BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia

  • Authors:
    • Lena Schmidlechner
    • Inga Nagel
    • Inga Vater
    • Ingolf Cascorbi
    • Meike Kaehler
  • View Affiliations

  • Published online on: July 4, 2024     https://doi.org/10.3892/ol.2024.14557
  • Article Number: 424
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The use of tyrosine kinase inhibitors, such as imatinib, against the chronic myeloid leukemia (CML)‑causing kinase BCR::ABL1 has become the model for successful targeted therapy. Nevertheless, drug resistance remains a clinical problem. Analysis of genome‑wide expression and genetic aberrations of an in vitro imatinib‑resistant CML cell line revealed downregulation of Bruton's tyrosine kinase (BTK), predominantly associated with B cell malignancies, and a novel BTK kinase domain variant in imatinib resistance. This raised the question of the role of BTK in imatinib‑resistant CML. In the present study, BTK downregulation and the presence of the BTK variant c.1699_1700delinsAG p.(Glu567Arg) were confirmed in imatinib resistance in vitro. Similarly, BTK inhibition or small interfering RNA‑mediated BTK knockdown reduced imatinib susceptibility by 84 and 71%, respectively. BTK overexpression was detrimental to CML cells, as proliferation was significantly reduced by 20.5% under imatinib treatment. In addition, BTK rescue in imatinib‑resistant cells restored imatinib sensitivity. The presence of the BTK p.(Glu567Arg) variant increased cell numbers (57%) and proliferation (37%) under imatinib exposure. These data demonstrate that BTK is important for the development of imatinib resistance in CML: Its presence increased drug response, while its absence promotes imatinib resistance. Moreover, the BTK p.(Glu567Arg) variant abrogates imatinib sensitivity. These findings demonstrate a context‑dependent role for BTK as an oncogene in B cell malignancies, but as a tumor suppressor in other neoplasms.
View Figures
View References

Related Articles

Journal Cover

September-2024
Volume 28 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Schmidlechner L, Nagel I, Vater I, Cascorbi I and Kaehler M: BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia. Oncol Lett 28: 424, 2024.
APA
Schmidlechner, L., Nagel, I., Vater, I., Cascorbi, I., & Kaehler, M. (2024). BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia. Oncology Letters, 28, 424. https://doi.org/10.3892/ol.2024.14557
MLA
Schmidlechner, L., Nagel, I., Vater, I., Cascorbi, I., Kaehler, M."BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia". Oncology Letters 28.3 (2024): 424.
Chicago
Schmidlechner, L., Nagel, I., Vater, I., Cascorbi, I., Kaehler, M."BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia". Oncology Letters 28, no. 3 (2024): 424. https://doi.org/10.3892/ol.2024.14557